Salute e Benessere
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
Global leaders such as are pioneering next-generation therapeutics. With strong regulatory backing, particularly from the , and rising investment in rare disease research, the neuromuscular therapeutics space is poised for sustained double-digit growth.
Novartis' for SMA and Sarepta's gene therapies for Duchenne muscular dystrophy highlight the transformative role of single-dose, potentially curative treatments. By 2033, gene therapies are expected to contribute nearly
continue to expand, with Biogen's leading SMA care and newer ASOs under development for ALS and myopathies.
are expanding in SMA and myositis, offering oral administration advantages.
driven by Argenx's and AstraZeneca's rare disease-focused biologics portfolio.
covering ASOs, monoclonal antibodies, and enzyme-based treatments.
led by small-molecule splicing modulators.
offering greater patient convenience.
The U.S. neuromuscular disease therapeutics market, valued at leads globally due to:
Japan's market, valued at is growing due to:
Novartis leads the SMA market with . Its strong pipeline in gene therapy reinforces long-term leadership.
Biogen dominates the ASO space with and is advancing ALS-specific RNA-based therapies. Its 2025 approval strengthens its neurology franchise.
Sarepta is pioneering Duchenne muscular dystrophy gene therapies. In 2024, its revenues crossed with new approvals expected in 2026.
Argenx is revolutionizing myasthenia gravis care with which achieved blockbuster status in 2024. Its complement inhibitor pipeline is expanding into other neuromuscular diseases.
Japanese leaders are focusing on Duchenne and rare myopathies, leveraging domestic and global collaborations.
The is undergoing a paradigm shift, defined by:
The is one of the fastest-growing segments in rare disease care. With leading breakthroughs, the decade ahead will be defined by
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/neuromuscular-disease-therapeutics-market-to-reach-us-45-62-billion-by-2033-as-gene-therapies-and-rna-based-treatments-redefine-patient-outcomes-302577125.html